HPV vaccination uptake and administration from 2006 to 2016 in a commercially insured population of the United States
Abstract Background Human papillomavirus (HPV) infection can cause various cancers and can be prevented through vaccination. The American Cancer Society (ACS) has set an HPV vaccination completion target in 13-year-old children to 80% by 2026. While HPV vaccine coverage (proportion ever vaccinated)...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-09-01
|
Series: | BMC Public Health |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12889-021-11664-1 |
id |
doaj-a37ba04ef0e04c949d9a1f1f632122df |
---|---|
record_format |
Article |
spelling |
doaj-a37ba04ef0e04c949d9a1f1f632122df2021-09-12T11:15:00ZengBMCBMC Public Health1471-24582021-09-012111910.1186/s12889-021-11664-1HPV vaccination uptake and administration from 2006 to 2016 in a commercially insured population of the United StatesVimalanand S. Prabhu0Neha Bansal1Zhiwen Liu2Rodney Finalle3Martin Sénécal4Smita Kothari5Kemar Trowers6Evan Myers7Center for Observational and Real-World Evidence, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., IncComplete HEOR Solutions (CHEORS)Center for Observational and Real-World Evidence, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., IncCenter for Observational and Real-World Evidence, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., IncComplete HEOR Solutions (CHEORS)Center for Observational and Real-World Evidence, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., IncCenter for Observational and Real-World Evidence, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., IncDivision of Women’s Community and Population Health, Department of Obstetrics & Gynaecology, Duke University Medical CenterAbstract Background Human papillomavirus (HPV) infection can cause various cancers and can be prevented through vaccination. The American Cancer Society (ACS) has set an HPV vaccination completion target in 13-year-old children to 80% by 2026. While HPV vaccine coverage (proportion ever vaccinated) estimates are available, annual uptakes (proportion initiating vaccine in a year) in the United States (U.S.) are not well-known. Methods We analyzed MarketScan® claims database to assess HPV vaccination uptakes in the U.S. among the 9- to 26-year-olds in 2006–2016. The annual uptake was the ratio of the number of enrollees who had a first record of an HPV vaccine during the year, and the number of enrollees of similar age and sex that year. Results Uptake was below 1% among children turning 9 and 10 years old during the year. Since 2009 among female and since 2013 among males, the annual uptake has been the highest in those turning 13 years old (19.7% among females and 17.6% among males in 2016). Catch-up vaccination among older adolescents and young adults increased after Advisory Committee for Immunization Practices (ACIP) recommendations, but eventually slowed down as more younger persons were vaccinated. Most young adolescents were vaccinated by pediatricians, whereas young adult women were predominantly vaccinated by obstetricians/gynecologists and young adult males by family physicians. While only about half of the adolescents had well-check visits, the majority of those who initiated HPV vaccination had one the same year. Conclusion Continued increase in uptake is needed to reach the ACS 2026 goals.https://doi.org/10.1186/s12889-021-11664-1Human papillomavirusHPV vaccineVaccination uptakeTemporal trendsSex differencesInsurance claims data |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Vimalanand S. Prabhu Neha Bansal Zhiwen Liu Rodney Finalle Martin Sénécal Smita Kothari Kemar Trowers Evan Myers |
spellingShingle |
Vimalanand S. Prabhu Neha Bansal Zhiwen Liu Rodney Finalle Martin Sénécal Smita Kothari Kemar Trowers Evan Myers HPV vaccination uptake and administration from 2006 to 2016 in a commercially insured population of the United States BMC Public Health Human papillomavirus HPV vaccine Vaccination uptake Temporal trends Sex differences Insurance claims data |
author_facet |
Vimalanand S. Prabhu Neha Bansal Zhiwen Liu Rodney Finalle Martin Sénécal Smita Kothari Kemar Trowers Evan Myers |
author_sort |
Vimalanand S. Prabhu |
title |
HPV vaccination uptake and administration from 2006 to 2016 in a commercially insured population of the United States |
title_short |
HPV vaccination uptake and administration from 2006 to 2016 in a commercially insured population of the United States |
title_full |
HPV vaccination uptake and administration from 2006 to 2016 in a commercially insured population of the United States |
title_fullStr |
HPV vaccination uptake and administration from 2006 to 2016 in a commercially insured population of the United States |
title_full_unstemmed |
HPV vaccination uptake and administration from 2006 to 2016 in a commercially insured population of the United States |
title_sort |
hpv vaccination uptake and administration from 2006 to 2016 in a commercially insured population of the united states |
publisher |
BMC |
series |
BMC Public Health |
issn |
1471-2458 |
publishDate |
2021-09-01 |
description |
Abstract Background Human papillomavirus (HPV) infection can cause various cancers and can be prevented through vaccination. The American Cancer Society (ACS) has set an HPV vaccination completion target in 13-year-old children to 80% by 2026. While HPV vaccine coverage (proportion ever vaccinated) estimates are available, annual uptakes (proportion initiating vaccine in a year) in the United States (U.S.) are not well-known. Methods We analyzed MarketScan® claims database to assess HPV vaccination uptakes in the U.S. among the 9- to 26-year-olds in 2006–2016. The annual uptake was the ratio of the number of enrollees who had a first record of an HPV vaccine during the year, and the number of enrollees of similar age and sex that year. Results Uptake was below 1% among children turning 9 and 10 years old during the year. Since 2009 among female and since 2013 among males, the annual uptake has been the highest in those turning 13 years old (19.7% among females and 17.6% among males in 2016). Catch-up vaccination among older adolescents and young adults increased after Advisory Committee for Immunization Practices (ACIP) recommendations, but eventually slowed down as more younger persons were vaccinated. Most young adolescents were vaccinated by pediatricians, whereas young adult women were predominantly vaccinated by obstetricians/gynecologists and young adult males by family physicians. While only about half of the adolescents had well-check visits, the majority of those who initiated HPV vaccination had one the same year. Conclusion Continued increase in uptake is needed to reach the ACS 2026 goals. |
topic |
Human papillomavirus HPV vaccine Vaccination uptake Temporal trends Sex differences Insurance claims data |
url |
https://doi.org/10.1186/s12889-021-11664-1 |
work_keys_str_mv |
AT vimalanandsprabhu hpvvaccinationuptakeandadministrationfrom2006to2016inacommerciallyinsuredpopulationoftheunitedstates AT nehabansal hpvvaccinationuptakeandadministrationfrom2006to2016inacommerciallyinsuredpopulationoftheunitedstates AT zhiwenliu hpvvaccinationuptakeandadministrationfrom2006to2016inacommerciallyinsuredpopulationoftheunitedstates AT rodneyfinalle hpvvaccinationuptakeandadministrationfrom2006to2016inacommerciallyinsuredpopulationoftheunitedstates AT martinsenecal hpvvaccinationuptakeandadministrationfrom2006to2016inacommerciallyinsuredpopulationoftheunitedstates AT smitakothari hpvvaccinationuptakeandadministrationfrom2006to2016inacommerciallyinsuredpopulationoftheunitedstates AT kemartrowers hpvvaccinationuptakeandadministrationfrom2006to2016inacommerciallyinsuredpopulationoftheunitedstates AT evanmyers hpvvaccinationuptakeandadministrationfrom2006to2016inacommerciallyinsuredpopulationoftheunitedstates |
_version_ |
1717755844954685440 |